Halley E. Gilbert - 31 May 2023 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
02 Jun 2023, 19:08:02 UTC
Prior SEC filing
17 Jun 2022
Next SEC filing
15 Jun 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Scott Burrows, as Attorney-in-Fact for Halley Gilbert

Key filing fact

Halley E. Gilbert filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 02 Jun 2023.

Key facts

  • This page summarizes Halley E. Gilbert's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 02 Jun 2023, 19:08.

Change

  • Previous filing in this sequence was filed on 17 Jun 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARQT transaction

Common Stock

Award

Transaction value
$0
Shares
+4,375
Change %
+101%
Price
$0.000000
Shares after
8,687
Date
31 May 2023
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARQT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+12,220
Change %
Price
$0.000000
Shares after
12,220
Date
31 May 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
12,220
Exercise price
$7.51
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Includes 4,375 Restricted Stock Units (?RSUs?). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.

Footnote F2

The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .